Notably, the administration of utrophin may offer advantages over large doses of the AAV-mini-dystrophin gene, potentially reducing the risk of immune responses observed in canine models of DMD and GRMD (Golden Retriever model for DMD). This evidence concerns the gene UTRN and Duchenne muscular dystrophy.